What is Sales and Marketing Strategy of Galapagos Company?

Built an EU5 footprint plus Benelux and Nordics after EC approvals (RA 2020; UC 2021) with Jyseleca sold through country affiliates and specialty channels.

Partners handle commercialization where scale or regulatory complexity favors collaboration, notably filgotinib partnerships in Japan with Gilead/Astellas.

Distribution via specialty distributors and wholesalers under SLAs covering cold-chain, pharmacovigilance and outcomes reporting to preserve market share and ensure compliance.

Model balances SG&A efficiency and market access; 2024 guidance targeted maintained cash runway beyond 2027, implying disciplined channel spend and mid-single to low-double-digit Jyseleca net sales growth in core EU markets.

Identity emphasizes clinical minimalism, EU-aligned visual cues, and an evidence-first, empathetic tone focused on benefit–risk transparency and reliable access for prescribers and patients.

Patients and HCPs receive clear risk management, responsive medical support, and structured access pathways, reinforced by modular materials and centralized MLR to ensure consistency.

Positioning rests on a focused specialty footprint with country-level market access excellence, credible clinical data and RWE generation, and pipeline optionality in inflammation and cell therapy.

Appeals to prescribers via value and safety stewardship—critical amid class-wide JAK safety scrutiny—rather than mass-market branding; updated value dossiers and head-to-head data strengthen the narrative.

Objective: build share in moderate-to-severe UC across EU5 after approval using evidence-focused KOL case films, MOA animation and access toolkits; channels included EULAR/UEG symposia, HCP portals, programmatic HCP media and payer-timed email sequences. Results: double-digit growth in UC TRx contribution within territories, improved formulary adoption in Germany and Spain and ~20% reduction in cost per HCP engagement via digital shift. Success factors: MSL-aligned content, localized HTA value messaging and agile approvals.

Objective: standardize next-best-action across affiliates using modular content mapped to prescriber journey stages; channels: Veeva CRM triggers, webinars, virtual detailing and LinkedIn thought leadership. Results: email open rates up 8–12%, qualified remote details increased 15–25%, and faster post-congress follow-up cycles. Lesson: real-time data + field feedback boosted relevance and reduced fatigue.

Objective: address JAK-class safety perceptions and refine patient selection through transparent safety dashboards, RWE digests and monitoring checklists; channels: accredited CME, specialty journals and payer briefings. Results: maintained prescriber confidence in targeted segments and supported reimbursement renewals in select markets. Success factors: third-party data credibility and KOL authorship.

Objective: secure/renew favorable hospital formulary positioning using country-specific economic models, budget-impact infographics and patient-pathway maps; channels: payer workshops, tender dossiers and pharmacy director roundtables. Results: tender wins in key hospital systems and stable share despite pricing pressure. Lesson: localized health-economics storytelling is decisive.